Our HTGF Portfolio of startups offers excellent opportunities and is always hiring talented people.
TQX will shift paradigms in cell and gene therapy. The TQX platform will transform the traditional way of producing cellular therapies, which is often slow, expensive, and hard to scale, into a very fast and highly automated process right at the patient's side. This method uses extra-corporeal gene therapy but keeps the benefits of autologous cell therapy, where patients receive treatments made from their own cells. Our TQX method makes it easier to create genetically modified immune cells (like CAR-T cells) and deliver cell therapy directly to the patient. This avoids the complicated and costly steps of centralized production. As a result, this approach unlocks the full potential of autologous cell therapies for treating conditions that were previously difficult to address, including rare autoimmune diseases and cancers.
Something looks off?